Lexicon Pharmaceuticals Revenue Growth: -54.55%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
LXRX Revenue Growth Rankings
| Overall | 1st percentile | 4345 of 4424 |
| Sector | 6th percentile | 436 of 464 in Healthcare |
| Industry | 13th percentile | 110 of 127 in Biotechnology |
LXRX Revenue Growth Range, Past 5 Years
| Minimum | -52.60% | Dec 2006 |
| Maximum | 319.46% | Mar 2000 |
| Average |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these LXRX related companies
LXRX News
Lexicon Pharmaceuticals to Present at the 14th Annual BIO CEO & Investor Conference
Feb 07, 6:00PM PR Newswire
Feb 07, 6:00PM PR Newswire
Lexicon Pharmaceuticals' CEO Presents at JP Morgan Healthcare Conference (Transcript)
Jan 11, 8:42PM Seeking Alpha
Jan 11, 8:42PM Seeking Alpha
Lexicon (LXRX) Says Top-Line Results from LX4211 Study Show Enhanced Effects with DPP-4
Jan 09, 4:41PM Street Insider
Jan 09, 4:41PM Street Insider
LX4211 Enhances Effects of DPP-4 Inhibition in Patients with Type 2 Diabetes
Jan 09, 4:30PM Benzinga
Jan 09, 4:30PM Benzinga
Lexicon Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Jan 04, 6:00PM PR Newswire
Jan 04, 6:00PM PR Newswire
Lexicon Pharmaceuticals (LXRX) Completes Offering with Gross Proceeds of $161 Million
Dec 23, 8:31AM Street Insider
Dec 23, 8:31AM Street Insider
FMR LLC Raises Stake in Lexicon Pharmaceuticals, Inc. (LXRX) to 17.55%
Dec 12, 11:43AM Street Insider
Dec 12, 11:43AM Street Insider
RT @sssc RT @stocktiger: Comprehensive Market Newsletter 60+ charts http://stks.co/1UHe with +s to WatchList $HNSN $LXRX $GMXR $BRLI $HSNI
about 63 days ago by hertcapital
about 63 days ago by hertcapital
Comprehensive Market Newsletter 60+ charts http://stks.co/1UFk with additions to WatchList $HNSN $LXRX $GMXR $BRLI $HSNI $FITB $CTCT
about 63 days ago by StockTiger
about 63 days ago by StockTiger
Lexicon to Present LX4211 Clinical and Preclinical Data at Diabetes Conference
Nov 03, 6:00PM PR Newswire
Nov 03, 6:00PM PR Newswire
Needham & Company Reiterates a 'Buy' on Lexicon Pharmaceuticals (LXRX); Q3 Review
Nov 02, 8:20AM Street Insider
Nov 02, 8:20AM Street Insider
Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results
Nov 01, 6:00AM PR Newswire
Nov 01, 6:00AM PR Newswire
Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2011 Financial Results
Oct 27, 6:00PM PR Newswire
Oct 27, 6:00PM PR Newswire
$LXRX http://stks.co/ZAO Hammer candle. Flagging at the 20MA. Like it with volume expansion.
about 125 days ago by VexTrades
about 125 days ago by VexTrades
$LXRX http://chart.ly/d5ep8gf hvy EOD volume. looks like a solid break out so far.
about 233 days ago by traderengineer
about 233 days ago by traderengineer
$LXRX http://chart.ly/uo3em8f jumped in. breaking trend on volume.
about 233 days ago by traderengineer
about 233 days ago by traderengineer
$LXRX http://chart.ly/ibwtlnq close to breakout.... nice action all day in this crap tape....
about 234 days ago by stt2318
about 234 days ago by stt2318
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| LXRX | 1.71 | -0.01 | -0.29% | 575.74M |
| CYTK | 1.18 | -0.01 | -0.84% | 85.29M |
| DGII | 11.86 | -0.27 | -2.23% | 304.09M |
| VISN | 1.50 | -0.08 | -5.06% | 153.38M |
| FORM | 5.28 | -0.21 | -3.83% | 266.43M |
| SCHW | 12.18 | -0.18 | -1.46% | 15.47B |
| CAVM | 33.12 | -0.91 | -2.67% | 1.61B |
| SWHC | 5.16 | -0.10 | -1.90% | 333.39M |
| FRED | 14.73 | -0.22 | -1.47% | 567.69M |
| NWSA | 19.18 | -0.04 | -0.18% | 33.02B |
